Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma.

Area of Science:

• Hematology
• Immunotherapy
• Oncology

Background:

• Relapsed/refractory multiple myeloma (R/R MM) remains a therapeutic challenge.
• The impact of chimeric antigen receptor T-cell (CAR-T) therapy on platelet function in R/R MM is not well understood.
• Platelet function plays a role in hemostasis and immune responses.

Purpose of the Study:

• To investigate the effect of CAR-T cell therapy on platelet function in R/R MM patients.
• To determine if platelet closure time (PCT) can serve as a prognostic biomarker for CAR-T therapy efficacy in R/R MM.

Main Methods:

• A cohort of 50 R/R MM patients treated with CAR-T cells was studied.
• Platelet closure time (PCT) was measured using collagen/adenosine diphosphate (CADP) before and after CAR-T cell therapy.
• Patient responses, progression-free survival (PFS), and overall survival (OS) were analyzed in relation to PCT values.

Main Results:

• CAR-T cell therapy significantly reduced PCT post-treatment compared to pre-treatment levels, indicating improved platelet function.
• Post-treatment PCT was comparable to healthy controls and showed enhancement in patients achieving a partial remission or better.
• An elevated PCT (>240.5 s) was associated with shorter PFS and identified as an independent negative prognostic factor for OS in R/R MM patients post-CAR-T therapy.

Conclusions:

• CAR-T cell therapy enhances platelet function in R/R MM patients.
• PCT is a potential prognostic biomarker for predicting CAR-T therapy efficacy and patient survival outcomes in R/R MM.